GlassScriptPhysician profile
Durre Ahmed
NPI 1407875909
$1,398.64
in general payments reported to CMS, 2019-2025
23 companies · $44.50 in 2025
The $44.50 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $111 · 2021: $385 · 2022: $343 · 2023: $212 · 2024: $74.99 · 2025: $44.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $331.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $142.87 | 2019-2023 | Xarelto |
| Biotronik INC. | $136.97 | 2021 | |
| Lilly USA, LLC | $134.49 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $121.60 | 2019-2023 | |
| Abbvie INC. | $99.88 | 2021-2023 | Vraylar |
| Novo Nordisk INC | $96.31 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $67.46 | 2021-2023 | Eliquis |
| Glaxosmithkline, LLC. | $61.58 | 2021-2024 | Arexvy, Shingrix |
| Astellas Pharma US INC | $61.46 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $54.53 | 2019-2021 | |
| Allergan, INC. | $54.15 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.93 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $50.03 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.70 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $46.63 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $39.47 | 2023 | Injectafer |
| Pfizer INC. | $38.39 | 2019-2022 | |
| Biogen, INC. | $24.49 | 2021-2022 | |
| Abbott Laboratories | $16.96 | 2023 | Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.54 | 2025 | Xifaxan |
| Exact Sciences Corporation | $13.61 | 2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $11.94 | 2019 | |
| Urovant Sciences INC | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Durre Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.